

# Early haemodynamic changes and long-term outcome of patients with severe low-gradient aortic stenosis after transcatheter aortic valve replacement



Jury Schewel<sup>1\*</sup>, MD; Michael Schlüter<sup>2</sup>, PhD; Tobias Schmidt<sup>1</sup>, MD; Karl-Heinz Kuck<sup>1</sup>, MD; Christian Frerker<sup>1</sup>, MD; Dimitry Schewel<sup>1</sup>, MD

1. Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany; 2. Asklepios proresearch, Hamburg, Germany

This paper also includes supplementary data published online at: <https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-19-00399>

## KEYWORDS

- aortic stenosis
- depressed left ventricular function
- TAVI

## Abstract

**Aims:** Approximately 40% of severe aortic stenosis (AS) patients have a low-gradient (<40 mmHg) AS (LG-AS). The aim of this study was to investigate the invasively measured haemodynamic changes and long-term outcome after transcatheter aortic valve replacement (TAVR) in the subgroups of LG-AS.

**Methods and results:** A total of 600 LG-AS patients with haemodynamic assessment by left and right heart catheterisation were divided into three groups: normal-flow (NFLG-AS; n=296), paradoxical low-flow (PLFLG-AS; n=153), and classic low-flow (CLFLG-AS; n=151). Post TAVR, PLFLG-AS and CLFLG-AS showed a significant reduction in global afterload ( $p<0.005$ ), as well as a significant elevation of stroke volume index (SVI), and left and right ventricular stroke work index ( $p<0.001$ ). NFLG-AS was associated with an elevation of global afterload and a decrease of SVI ( $p<0.05$ ). Overall survival was highest in NFLG-AS, followed by PLFLG-AS and CLFLG-AS. All subgroups experienced similar symptomatic improvement.

**Conclusions:** NFLG-AS was the most prevalent form of LG severe AS and was associated with adequate left ventricular compensation and good prognosis. On the other hand, CLFLG-AS represents the heart failure with reduced ejection fraction (HFrEF) form of AS and was associated with the worst prognosis, whereas PLFLG-AS represents the heart failure with preserved ejection fraction (HFpEF) form of AS with intermediate prognosis. Both groups showed early haemodynamic reverse response after TAVR.

\*Corresponding author: Department of Cardiology, Marienkrankenhaus Hamburg, Alfredstr. 9, 22087 Hamburg, Germany.  
E-mail: [jury.schewel@gmail.com](mailto:jury.schewel@gmail.com)

## Abbreviations

|              |                                        |
|--------------|----------------------------------------|
| <b>AS</b>    | aortic stenosis                        |
| <b>LG-AS</b> | low-gradient aortic stenosis           |
| <b>LVEF</b>  | left ventricular ejection fraction     |
| <b>MG</b>    | mean transvalvular pressure gradient   |
| <b>SVI</b>   | stroke volume index                    |
| <b>TAVR</b>  | transcatheter aortic valve replacement |

## Introduction


Calcific aortic stenosis (AS) is the most frequent heart valve disease in developed countries<sup>1</sup>. When patients with severe AS develop symptoms, effective treatment by surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) is necessary to reduce mortality and improve symptoms. Usually, standard transthoracic echocardiography is an appropriate imaging modality to evaluate disease severity. Thereby, severe AS is defined as aortic valve area (AVA)  $\leq 1.0 \text{ cm}^2$  or indexed AVA (AVAi)  $\leq 0.6 \text{ cm}^2/\text{m}^2$ , and a mean transvalvular gradient (MG)  $\geq 40 \text{ mmHg}$ <sup>2</sup>. However, in about 40% of AS patients, echocardiographic findings are discordant and multimodality imaging is required. The most common constellation is called “low-gradient AS” (LG-AS) with a small AVA ( $\leq 1.0 \text{ cm}^2$ ) and low MG ( $< 40 \text{ mmHg}$ ) and is associated with uncertainties regarding disease severity and therapeutic management<sup>2-8</sup>. According to the current European guidelines, LG-AS should be divided into three subgroups depending on flow pattern and left ventricular ejection fraction (LVEF): classic low-flow, low-gradient AS (CLFLG-AS) with reduced LVEF; paradoxical low-flow, low-gradient AS (PLFLG-AS) with preserved LVEF but reduced stroke volume index (SVI); and normal-flow, low-gradient AS (NFLG-AS) with preserved LVEF and SVI. According to the European guidelines, AVR is recommended in CLFLG-AS and PLFLG-AS (class IIa<sup>2</sup>). For NFLG-AS there are no specific recommendations. These patients are more likely to have moderate AS, although recent studies have shown that approximately 50% have severe AS<sup>8,9</sup>. Regarding PLFLG-AS, conflicting results concerning the outcome and benefit of AVR have been published<sup>8,10,11</sup>. To provide optimal therapy, multimodality imaging before and after AVR is necessary to understand the pathophysiology<sup>2-4</sup>. Although previously published studies provide evidence of echocardiographic improvement after AVR<sup>7,12-15</sup>, there are no invasively measured data showing haemodynamic changes after AVR<sup>7,16,17</sup>. Therefore, the objective of the present study was to evaluate the invasive measurements before and directly after TAVR to gain more insight into the haemodynamic changes and to understand which of the entities benefits most.

## Methods

### PATIENT POPULATION AND STUDY DESIGN

Six hundred (600) LG-AS patients (invasively measured AVA  $\leq 1.0 \text{ cm}^2$  or indexed AVA [AVAi]  $\leq 0.6 \text{ cm}^2/\text{m}^2$ ; invasively measured MG [MG (invasive)]  $< 40 \text{ mmHg}$ ) with full invasive haemodynamic assessment before and after TAVR, who were treated between September 2009 and November 2017 in our hospital

were included. The patients were divided into three groups according to the guidelines<sup>2</sup>: NFLG-AS (n=296; LVEF  $\geq 50\%$ , stroke volume index [SVI]  $> 35 \text{ ml}/\text{cm}^2$ ); PLFLG-AS (n=153; LVEF  $\geq 50\%$ ; SVI  $\leq 35 \text{ ml}/\text{cm}^2$ ); CLFLG-AS (n=151; LVEF  $< 50\%$ ) (Figure 1). All patients underwent extended echocardiographic examination as well as haemodynamic assessment by left and right heart catheterisation directly before and after the TAVR procedure. A detailed specification of the parameters which were assessed and calculated is provided in Supplementary Appendix 1.



**Figure 1.** Flow chart of patient population selection. AS: aortic stenosis; AVA: aortic valve area; AVAi: indexed AVA; CLFLG: classic low-flow low-gradient; LVEF: left ventricular ejection fraction; MG (invasive): invasively measured mean transvalvular gradient; NFLG: normal-flow low-gradient; PLFLG: paradoxical low-flow low-gradient; SVI: invasively measured stroke volume index

### TRANSCATHETER AORTIC VALVE IMPLANTATION PROCEDURE

A Heart Team consisting of an interventional cardiologist, a cardiac surgeon, and an anaesthesiologist evaluated severe symptomatic AS patients and made the final decision for TAVR procedures. TAVR procedures were performed using standard techniques. According to the device availability at different time points, commercially available valves were implanted via a transfemoral (n=515), transaxillary (n=36), transapical (n=43), or transaortic (n=6) access. Clinical outcomes were assessed according to the Valve Academic Research Consortium (VARC)-2 criteria<sup>18</sup>. Cause of death and complications after TAVR, as well as New York Heart Association (NYHA) functional class at six-month, one-year and maximum follow-up of 8.5 years were collected.

### STATISTICAL ANALYSIS

Continuous variables are described as means and standard deviations or medians and interquartile range (IQR), as appropriate; they were compared by one-way analysis of variance (ANOVA)

with *post hoc* Bonferroni correction for multiple comparisons and t-tests. Categorical data are described with absolute and relative frequencies and compared using Fisher's exact test. A two-tailed p-value <0.05 was considered statistically significant, except for multiple (n=3) two-group comparisons, for which p<0.0167 was considered statistically significant. Hazard ratios (HR) were calculated in a multivariable analysis, including all variables with a p-value <0.05 in the univariate analysis, and were used to determine independent predictors of one-year mortality after TAVR. A p-value <0.05 was considered statistically significant. Kaplan-Meier analysis was used to estimate the incidence of clinical outcomes at one- and five-year follow-up. Statistical analyses were performed with Statistical Package for Social Sciences, version 20.0.0 (IBM Corp., Armonk, NY, USA).

## Results

### PATIENTS' CLINICAL CHARACTERISTICS

Mean age was 81.0±6.6 years, and 49.2% of the patients were female. Females were significantly more prevalent (64.7%) among PLFLG-AS than among NFLG-AS (48.6%) or CLFLG-AS

(34.4%), whereas males more often had CLFLG-AS. CLFLG-AS, as opposed to PLFLG-AS or NFLG-AS, showed higher operative risk scores, significantly more often had coronary artery disease, and presented more often in NYHA Class ≥III. PLFLG-AS patients markedly more often had atrial fibrillation than NFLG-AS patients and more often had arterial hypertension than CLFLG-AS patients (Table 1).

### ECHOCARDIOGRAPHIC AND LABORATORY CHARACTERISTICS

CLFLG-AS presented with significantly lower LVEF, tricuspid annular plane systolic excursion (TAPSE), and thinner posterior wall, more dilated LV, and a higher prevalence of mitral regurgitation (MR) compared to both of the other groups. Furthermore, NFLG-AS had significantly greater AVA and higher MG measured by echocardiography (MG [echo]). Moreover, these individuals had a lower prevalence of tricuspid regurgitation (TR) compared to CLFLG-AS, and lower LVEF than PLFLG-AS (Table 2, Supplementary Figure 1, Moving image 1A, Moving image 1B, Moving image 2A, Moving image 2B, Moving image 3A, Moving

Table 1. Baseline demographics.

|                                     |     | ALL<br>n=600     | NFLG-AS<br>n=296 | PLFLG-AS<br>n=153 | CLFLG-AS<br>n=151  | p-value |
|-------------------------------------|-----|------------------|------------------|-------------------|--------------------|---------|
| Male                                |     | 305 (50.8)       | 152 (51.4)*†     | 54 (35.3)*‡       | 99 (65.6)‡†        | <0.001  |
| Age, years                          |     | 81.0±6.6         | 80.9±6.6         | 81.8±7.2          | 80.5±7.6           | 0.229   |
| BMI, kg/cm <sup>2</sup>             |     | 26.1±5.1         | 26.0±4.7         | 26.5±5.4          | 25.8±5.7           | 0.512   |
| Logistic EuroSCORE, %               |     | 16.4 [10.2-27.5] | 15.1 [9.5-22.8]† | 13.4 [10.0-22.4]‡ | 25.4 [14.8-40.3]‡† | <0.001  |
| EuroSCORE II, %                     |     | 5.1 [3.9-7.5]    | 4.8 [3.7-6.4]†   | 5.2 [4.2-7.2]‡    | 6.0 [4.3-11.5]‡†   | <0.001  |
| STS-PROM, %                         |     | 5.1 [3.4-7.9]    | 4.6 [3.2-6.9]†   | 5.1 [3.3-7.9]     | 5.9 [3.8-10.1]†    | 0.016   |
| Arterial hypertension               |     | 504 (84.0)       | 250 (84.5)       | 138 (90.2)‡       | 116 (76.8)‡        | 0.006   |
| Coronary artery disease             |     | 402 (67.0)       | 191 (64.5)†      | 95 (62.1)‡        | 116 (76.8)‡†       | 0.011   |
| Porcelain aorta                     |     | 83 (13.8)        | 41 (13.9)        | 25 (16.3)         | 17 (11.3)          | 0.445   |
| Previous cardiac surgery            |     | 95 (15.8)        | 45 (15.2)        | 22 (14.4)         | 28 (18.5)          | 0.574   |
| Impaired renal function§            |     | 392 (65.3)       | 190 (64.2)       | 102 (66.7)        | 100 (66.2)         | 0.854   |
| Haemodialysis                       |     | 18 (3.0)         | 7 (2.4)          | 7 (4.6)           | 4 (2.6)            | 0.489   |
| Hyperlipidaemia                     |     | 249 (41.5)       | 126 (42.6)       | 60 (39.2)         | 63 (41.7)          | 0.798   |
| Diabetes mellitus                   |     | 197 (32.8)       | 98 (33.1)        | 44 (28.8)         | 55 (36.4)          | 0.364   |
| Atrial fibrillation                 |     | 330 (55.0)       | 146 (49.3)*      | 97 (63.4)*        | 87 (57.6)          | 0.013   |
| COPD                                |     | 115 (19.2)       | 62 (20.9)        | 26 (17.0)         | 27 (17.9)          | 0.542   |
| Pulmonary hypertension <sup>Δ</sup> |     | 110 (18.3)       | 46 (15.5)        | 28 (18.3)         | 36 (23.8)          | 0.102   |
| NYHA functional class               | I   | 13 (2.2)         | 9 (3.0)          | 2 (1.3)           | 2 (1.3)            | 0.0045  |
|                                     | II  | 53 (8.8)         | 30 (10.1)        | 19 (12.4)         | 4 (2.6)            |         |
|                                     | III | 432 (72.0)       | 219 (74.0)       | 103 (67.3)        | 110 (72.8)         |         |
|                                     | IV  | 102 (17.0)       | 38 (12.8)        | 29 (19.0)         | 35 (23.2)          |         |
| History of syncope                  |     | 83 (13.8)        | 37 (12.5)        | 26 (17.0)         | 20 (13.2)          | 0.423   |

All values are mean±SD, median [interquartile range] or n (%). \*p<0.0167 for NFLG-AS vs PLFLG-AS. †p<0.0167 for NFLG-AS vs CLFLG-AS.

‡p<0.0167 for CLFLG-AS vs PLFLG-AS. §Glomerular filtration rate <60 mL/min/1.73 m<sup>2</sup>. ΔSystolic pulmonary artery pressure ≥60 mmHg. AS: aortic stenosis; BMI: body mass index; CLFLG: classic low-flow low-gradient; COPD: chronic obstructive pulmonary disease; EuroSCORE: European System for Cardiac Operative Risk Evaluation; NFLG: normal-flow low-gradient; NYHA: New York Heart Association; PLFLG: paradoxical low-flow low-gradient; STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality

**Table 2. Echocardiographic data and biomarkers.**

|                                              | ALL<br>n=600           | NFLG-AS<br>n=296                    | PLFLG-AS<br>n=153                   | CLFLG-AS<br>n=151                   | p-value |
|----------------------------------------------|------------------------|-------------------------------------|-------------------------------------|-------------------------------------|---------|
| <b>Transthoracic echocardiography</b>        |                        |                                     |                                     |                                     |         |
| AVA, cm <sup>2</sup>                         | 0.84±0.22              | 0.87±0.23 <sup>‡</sup>              | 0.84±0.21                           | 0.78±0.20 <sup>‡</sup>              | <0.001  |
| AVA index, cm <sup>2</sup> /m <sup>2</sup>   | 0.46±0.13              | 0.48±0.13 <sup>‡</sup>              | 0.47±0.16                           | 0.43±0.12 <sup>‡</sup>              | <0.001  |
| Aortic peak velocity, m/s                    | 3.6±2.6                | 3.8±3.2                             | 3.6±2.3                             | 3.2±0.6                             | 0.094   |
| Maximal gradient, mmHg                       | 49.2±15.2              | 53.1±14.8* <sup>‡</sup>             | 48.4±14.5* <sup>‡</sup>             | 42.3±14.1 <sup>‡</sup>              | <0.001  |
| Mean transvalvular gradient, MG (echo), mmHg | 29.7±9.8               | 31.8±8.1 <sup>‡</sup>               | 29.0±9.1                            | 26.2±9.7 <sup>‡</sup>               | <0.001  |
| LVEF, %                                      | 49.0±14.2              | 52.8±12.2* <sup>‡</sup>             | 58.5±4.1* <sup>‡</sup>              | 31.9±8.9 <sup>‡</sup>               | <0.001  |
| E/E' ratio                                   | 15.2±6.6               | 14.6±6.4 <sup>‡</sup>               | 14.3±6.0 <sup>‡</sup>               | 17.3±7.1 <sup>‡</sup>               | <0.001  |
| IVS, mm                                      | 13.1±3.7               | 13.6±4.6 <sup>‡</sup>               | 13.3±2.0                            | 12.0±2.6 <sup>‡</sup>               | 0.002   |
| PW, mm                                       | 12.8±3.8               | 13.2±4.9 <sup>‡</sup>               | 12.9±1.9 <sup>‡</sup>               | 12.0±2.6 <sup>‡</sup>               | 0.012   |
| LA diameter, mm                              | 46.8±6.5               | 45.9±6.5 <sup>‡</sup>               | 47.0±6.4                            | 48.4±6.2 <sup>‡</sup>               | 0.002   |
| LVEDD, mm                                    | 35.5±11.0              | 34.2±10.7* <sup>‡</sup>             | 29.9±6.9* <sup>‡</sup>              | 44.8±9.7 <sup>‡</sup>               | <0.001  |
| LVEDD, mm                                    | 50.3±8.4               | 49.3±8.5 <sup>‡</sup>               | 47.6±6.4 <sup>‡</sup>               | 55.2±8.1 <sup>‡</sup>               | <0.001  |
| Relative wall thickness                      | 0.54±0.39              | 0.57±0.54                           | 0.56±0.14                           | 0.45±0.16                           | 0.077   |
| TAPSE, mm                                    | 17.3±4.9               | 19.0±4.8* <sup>‡</sup>              | 17.4±4.3* <sup>‡</sup>              | 14.0±3.9 <sup>‡</sup>               | <0.001  |
| Aortic regurgitation ≥II                     | 154 (25.7)             | 67 (22.6)                           | 43 (28.1)                           | 44 (29.1)                           | 0.237   |
| Mitral regurgitation ≥II                     | 296 (49.3)             | 126 (42.6) <sup>‡</sup>             | 75 (49.0) <sup>‡</sup>              | 95 (62.9) <sup>‡</sup>              | <0.001  |
| Tricuspid regurgitation ≥II                  | 227 (37.8)             | 90 (30.4) <sup>‡</sup>              | 62 (40.5)                           | 75 (49.7) <sup>‡</sup>              | <0.001  |
| <b>Biomarkers</b>                            |                        |                                     |                                     |                                     |         |
| CRP, mg/l                                    | 20.3±32.3              | 17.4±26.4                           | 20.5±39.1                           | 25.8±34.5                           | 0.034   |
| Creatinine, mg/dl                            | 1.38±0.98              | 1.32±0.90                           | 1.38±1.13                           | 1.47±1.00                           | 0.320   |
| GFR, mL/min                                  | 52.0±19.9              | 53.1±19.6                           | 51.3±19.4                           | 50.5±20.9                           | 0.402   |
| NT-proBNP, ng/dl                             | 3,139<br>[2,745-3,534] | 2,126<br>[1,754-2,498] <sup>‡</sup> | 2,301<br>[1,755-2,847] <sup>‡</sup> | 6,272<br>[5,049-7,495] <sup>‡</sup> | <0.001  |

All values are mean±SD, median [interquartile range] or n (%). \*p<0.0167 for NFLG-AS vs PLFLG-AS. <sup>‡</sup>p<0.0167 for NFLG-AS vs CLFLG-AS. <sup>‡</sup>p<0.0167 for CLFLG-AS vs PLFLG-AS. AS: aortic stenosis; AVA: aortic valve area; CLFLG: classic low-flow low-gradient; CRP: C-reactive protein; GFR: glomerular filtration rate; IVS: interventricular septum; LA: left atrium; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; NFLG: normal-flow low-gradient; NT-proBNP: N-terminal pro-brain natriuretic peptide; PLFLG: paradoxical low-flow low-gradient; PW: left ventricular posterior wall; TAPSE: tricuspid annular plane systolic excursion

**image 3B**). In the laboratory tests, CLFLG-AS presented with markedly higher levels of NT-proBNP, while similar levels were documented in both of the other groups.


#### ACUTE HAEMODYNAMIC CHANGES POST TAVR

Significant increase in AVA and decreases in MG (invasive) and valvular resistance (VR) were documented in all patients, whereas a significant decrease of systemic vascular resistance index (SVRI) was noted in PLFLG-AS. CLFLG-AS was associated with still elevated SVRI after TAVR. Consequently, PLFLG-AS and CLFLG-AS had a significant decrease of valvuloarterial impedance (Zva), whereas NFLG-AS had a statistically significant, but clinically not relevant increase of Zva (**Supplementary Table 1, Figure 2, Supplementary Figure 2, Supplementary Figure 3**). Significant elevations in LV end-diastolic (LVEDP) and pulmonary capillary wedge pressures (PCWP) were observed in all patients. While SVI, cardiac output (CO), cardiac index (CI), left ventricular stroke work

index (LVSWI), and left cardiac work index (LCWI) were significantly increased in PLFLG-AS and CLFLG-AS, NFLG-AS exhibited a decrease of SVI after TAVR. Increases in pulmonary artery (PAP) and right arterial pressures (RAP) were noticed in all patients. While pulmonary vascular resistance index (PVRI) was normal before TAVR and unchanged in NFLG-AS after TAVR, it was moderately increased in CLFLG-AS before, and decreased significantly after valve deployment. In PLFLG-AS, the slightly elevated pulmonary resistances at baseline did not change after TAVR. Right ventricular function, left ventricular stroke work index (RVSWI) and left cardiac work index (RCWI) were normal at baseline in all patients and improved in PLFLG-AS and CLFLG-AS, but not in NFLG-AS, after TAVR.

#### OUTCOMES

Acute device success was 95.8%, with correct positioning of one prosthesis in 99.3% of cases. Eight patients had moderate-to-severe



**Figure 2.** Haemodynamic parameters in the LG-AS subgroups. Box plots of selected haemodynamic parameters pre (blue) and post TAVR (green) according to LG-AS subgroup. \* $p < 0.05$  for pre versus post TAVR. LG-AS: low-gradient aortic stenosis

paravalvular regurgitation despite post-dilatation. In four patients, MG (invasive) was  $\geq 20$  mmHg after TAVR. Four patients required conversion to open heart surgery, two patients due to ventricular embolisation of the prosthesis, and two patients due to myocardial perforation. Overall in-hospital stroke rate was 5.0%. Life-threatening or disabling bleedings occurred in 38 patients, while overall major bleedings were observed in 14.5% (**Supplementary Table 2**). Overall survival at one and five years was highest in NFLG-AS (**Figure 3A-Figure 3C**). Freedom from cardiovascular death at one year was similar in NFLG-AS and PLFLG-AS, and higher in CLFLG-AS (**Figure 3B**), which gained more expression after five years (**Figure 3D**). While baseline NYHA class differed significantly among the subgroups, with the most common occurrence of NYHA Class  $\geq$ III being in CLFLG-AS ( $p=0.006$ ), the functional class after TAVR was not significantly different among the three subgroups at six ( $p=0.354$ ) and 12 months ( $p=0.212$ ) (**Figure 4**).


## PREDICTORS OF ONE-YEAR MORTALITY

In a multivariable analysis of NFLG-AS, age (hazard ratio [HR] 1.09, 95% confidence interval [CI]: 1.05-1.14) and pulmonary hypertension (HR 2.92, 95% CI: 1.65-5.14) were shown to be independent predictors for one-year mortality. In PLFLG-AS, only age (HR 1.06, 95% CI: 1.00-1.12) was predictive for death. In CLFLG-AS, age and atrial fibrillation were significant predictors in the univariate analysis but not in the multivariable analysis (**Supplementary Table 3**).

## Discussion

This is the first retrospective study analysing early invasively measured haemodynamic changes and long-term outcomes in different subgroups of LG-AS patients undergoing TAVR. The main findings can be summarised as follows:


1. PLFLG-AS is typically accompanied by increased global after-load due to increased systemic and valvular resistances, and



**Figure 3.** Kaplan-Meier curves for all-cause (A & C) and cardiovascular (B & D) survival at one year and five years according to LG-AS subgroup. LG-AS: low-gradient aortic stenosis

- by haemodynamically measured impaired systolic LV function despite a preserved LVEF.
- CLFLG-AS patients have the most impaired haemodynamics, with significantly decreased LV function and increased systemic and pulmonary resistances.
- NFLG-AS is associated with almost regular haemodynamic parameters and showed less clinically relevant changes after TAVR.

- In PLFLG-AS and CLFLG-AS, TAVR leads to haemodynamic improvement directly at the end of the procedure.
  - Overall survival at one and five years was highest in NFLG-AS, followed by PLFLG-AS and lowest in CLFLG-AS.
- The pathophysiology of the different LG-AS entities is very complex. This challenging topic has been brought into focus regarding the diagnostic uncertainties and treatment strategy, due to the fact that over 40% of all patients with severe AS have



**Figure 4.** New York Heart Association (NYHA) functional class. A) Baseline. B) Six months. C) 12 months. LG-AS: low-gradient aortic stenosis

a low-gradient status<sup>2-8</sup>. Multimodality imaging and haemodynamic assessment are necessary to obtain more insight into the pathophysiology in order to facilitate decision making – observation versus conservative treatment versus AVR<sup>4-6,8</sup>.

#### NORMAL-FLOW, LOW-GRADIENT AORTIC STENOSIS

NFLG-AS represents the largest entity of LG-AS (approximately 50%)<sup>4</sup>, but less is known about the pathomechanism. This entity was first described by Hachicha et al in 2007<sup>2,19</sup>. Currently, the guidelines advise a re-evaluation of the measurements, and declare that moderate AS is more likely in this patient group. Finally, there is no recommendation on specific therapeutic management<sup>2</sup>. Nevertheless, conflicting data were published by Minners et al who described a discrepancy between the cut-off values and suggested that an AVA  $\leq 1.0$  cm<sup>2</sup> might more likely correspond to an MG of 30-35 mmHg rather than 40 mmHg<sup>20</sup>. However, other authors suggest that approximately 50% of cases have severe AS, and that symptomatic patients benefit from AVR<sup>8,9</sup>. The HAVEC group categorised this entity as “stage D4” and recommended performing multislice computed tomography with aortic valve calcium scoring to verify the severity stage<sup>3</sup>. In our study, only symptomatic high-risk patients with significantly elevated levels of both NT-proBNP and calcium score, in the absence of other reasons for symptoms, were considered for TAVR. Compared to regular RV and LV function at the baseline echocardiography, in the invasive haemodynamic tests only slightly decreased LV function (LVSWI) with elevated PCWP was assessed. These findings suggest that a symptomatic NFLG state represents less advanced but already ongoing cardiac damage (stage 1-2 according to Génèreux et al<sup>21</sup>). Carter-Storch et al analysed echocardiographic findings in NFLG-AS (n=33) and suggested that this entity probably has less severe AS with less reverse remodelling after AVR but benefits via a reduction of symptoms<sup>14</sup>. The smaller haemodynamic improvement in the present subgroup of NFLG-AS supports this suggestion. Furthermore, multiple studies have shown that NFLG-AS

benefits from AVR more compared to conservative treatment<sup>5,8,22</sup>. In our patients, overall one- and five-year mortality was lower in NFLG-AS compared to the other two groups. Thus, these findings support the fact that NFLG-AS has the best prognosis compared to the other two subgroups, as previously described<sup>5,8</sup>.

#### PARADOXICAL LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS

PLFLG-AS was first described in 2007 by Hachicha et al and is observed in 5-15% of severe AS patients<sup>19</sup>. It was suggested that, in contrast to CLFLG-AS, PLFLG-AS patients can be referred to as having “heart failure with preserved ejection fraction” (HFpEF)<sup>4</sup>. Typically, these patients are more often female, with arterial hypertension, atrial fibrillation, and a small LV cavity due to established concentric remodelling, with restrictive functionality and pronounced LV diastolic dysfunction. These factors, as well as significant MR or TR, lead to a low-flow status, despite a preserved LVEF<sup>6,19,23-25</sup>. Partially, this constellation was able to be proved in the present analysis. Both echocardiographic (E/E') and invasive measurements (LVEDP) documented a diastolic function similar to NFLG-AS. However, the haemodynamic assessments provided evidence of more advanced impairment of LV function. Moreover, while RV function was still preserved, propagation of LV impairment was reflected in increased pulmonary resistances and pressures, resulting in more elevated RAP. As was suspected previously by measurements of global longitudinal strain, these findings emphasise that LVEF quantification by echocardiography overestimates LV function in these patients, which actually seems to be in a more advanced stage of cardiac damage (stage 2-3)<sup>15,21</sup>. Furthermore, it was observed that impaired longitudinal LV function has been found to improve after AVR as a sign of reverse remodelling<sup>15,24</sup>, which is supported by our haemodynamic results with improvement of LV and RV function, and global afterload.

Our results support the findings of previous studies which showed a very similar survival in PLFLG-AS and CLFLG-AS patients, and a significantly better outcome in NFLG-AS patients<sup>26</sup>.

Regardless of the mechanism of reduced flow, these patients are at an advanced stage of the disease and benefit from TAVR.

### CLASSIC LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS

This entity can be found in 5-15% of severe AS<sup>26</sup> and is associated with male individuals, ischaemic cardiomyopathy and increased operative risk<sup>5</sup>. It is well documented that CLFLG-AS patients have the worst outcome, regardless of treatment by SAVR or TAVR. These patients have larger LV dimensions, impaired LV and RV function, and a higher prevalence of significant MR<sup>5</sup>. Accordingly, invasive haemodynamic assessments revealed severely decreased LV systolic and diastolic function. As a consequence of the severely advanced cardiac damage, pulmonary haemodynamics (resistance and pressures) and RV function are impaired most compared to the other two entities. These patients represent the heart failure with reduced ejection fraction (HFrEF) form of AS. Happily, our invasive measurements support previous echocardiographic studies which demonstrated reverse remodeling with improvement in LV and RV function after AVR, especially in CLFLG-AS patients<sup>12-14</sup>.

### Limitations

The limiting aspects of the present investigation are as follows. This was a retrospective analysis, although the data were collected prospectively. Due to the fact that haemodynamic measurements were performed directly prior to TAVR, there could be some discordant findings in measurements depending on sedation and volume status. Although computed tomography including measurements of the extent of aortic valve calcification were performed, these data have not been analysed in detail. No stress echo data routinely exist for CLFLG-AS. In elderly patients with a low-flow state, invasive measurement of AVA could underestimate AVA compared to echocardiography<sup>27</sup>.

### Conclusions

Severe symptomatic low-gradient AS is almost as prevalent as high-gradient AS (approximately 40%), but less is known about the outcome and early changes of haemodynamics after TAVR in these patients. In the present study, we were able to show that NFLG-AS was the most prevalent form of LG severe AS and was associated with adequate left ventricular compensation, less improvement of haemodynamics after TAVR and best survival compared to the other two entities. These patients seem to be at the early stage of severe AS disease, becoming either PLFLG-AS or CLFLG-AS if the disease progresses. While CLFLG-AS represents the HFrEF form of AS, which gives the impression of “end-stage” cardiac damage with poor prognosis, PLFLG-AS represents the HFpEF form of AS and correspondingly showed depressed systolic function in the haemodynamic assessment despite a preserved LVEF with intermediate prognosis. Both groups showed a significant improvement in haemodynamics after TAVR compared to NFLG-AS. Further analyses are needed to assess changes in haemodynamics and their impact on long-term mortality after TAVR.

### Impact on daily practice

Multimodality imaging and haemodynamic assessment are the key points for understanding the stage of severity of low-gradient aortic stenosis. By an invasive work-up, we were able to demonstrate different pathways and outcomes of AS entities: CLFLG-AS represents the HFrEF form of AS and was associated with the worst prognosis, whereas PLFLG-AS represents the HFpEF form of AS with intermediate prognosis. Both groups showed early haemodynamic improvement after TAVR. On the other hand, NFLG-AS was the most prevalent form of severe LG-AS and was associated with adequate left ventricular compensation, less haemodynamic improvement and good prognosis after TAVR. Additional large multicentre studies are needed to assess the optimal imaging work-up and the optimal therapy strategy for LG-AS subgroups.

### Conflict of interest statement

C. Frerker has been working as a proctor for St. Jude Medical, Medtronic, and Boston Scientific and has received lecture honoraria from Edwards Lifesciences. T. Schmidt has received lecture honoraria from Medtronic. K-H. Kuck reports having received consulting fees/honoraria from Biosense Webster, Medtronic, Boston Scientific, and St. Jude Medical. The other authors have no conflicts of interest to declare.

### References

- Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, Lereun CM, Bogers AJ, Piazza N, Kappetein AP. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. *J Am Coll Cardiol*. 2013;62:1002-12.
- Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Muñoz DR, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38:2739-91.
- Dulgheru R, Pibarot P, Sengupta PP, Piérard LA, Rosenhek R, Magne J, Donal E, Bernard A, Fattouch K, Cosyns B, Vannan M, Gillam L, Lancellotti P. Multimodality Imaging Strategies for the Assessment of Aortic Stenosis. *Circ Cardiovasc Imaging*. 2016;9:e004352.
- Clavel MA, Burwash IG, Pibarot P. Cardiac Imaging for Assessing Low-Gradient Severe Aortic Stenosis. *JACC Cardiovasc Imaging*. 2017;10:185-202.
- Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, Tuzcu EM, Babaliaros V, Thourani V, Szeto WY, Bavaria JE, Kodali S, Hahn RT, Williams M, Miller DC, Douglas PS, Leon MB. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. *Circulation*. 2013;127:2316-26.
- Pibarot P, Dumesnil JG. Paradoxical low-flow, low-gradient aortic stenosis: new evidence, more questions. *Circulation*. 2013;128:1729-32.
- O'Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N, Buellesfeld L, Khatib AA, Nietlispach F, Moschovitis A, Zanchin T, Meier B, Windecker S, Wenaweser P. Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. *Eur Heart J*. 2013;34:3437-50.

8. Tribouilloy C, Rusinaru D, Maréchaux S, Castel AL, Debry N, Maizel J, Mentaverri R, Kamel S, Slama M, Lévy F. Low-gradient, low-flow severe aortic stenosis with preserved left ventricular ejection fraction: characteristics, outcome, and implications for surgery. *J Am Coll Cardiol*. 2015;65:55-66.
9. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, Michelena HI, Cuffe C, Larose E, Capoulade R, Vahanian A, Enriquez-Sarano M. The complex nature of discordant severe calcified aortic valve disease grading: new insights from combined Doppler echocardiographic and computed tomographic study. *J Am Coll Cardiol*. 2013;62:2329-38.
10. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariha S, Picard MH, Hung J. Differential left ventricular remodelling and longitudinal function distinguishes low flow from normal-flow preserved ejection fraction low-gradient severe aortic stenosis. *Eur Heart J*. 2013;34:1906-14.
11. Maes F, Boulif J, Piérard S, De Meester C, Melchior J, Gerber B, Vancraeynest D, Pouleur AC, Lazam S, Pasquet A, Vanoverschelde JL. Natural history of paradoxical low-gradient severe aortic stenosis. *Circ Cardiovasc Imaging*. 2014;7:714-22.
12. Spethmann S, Baldenhofer G, Dreger H, Stürer K, Sanad W, Saghabalyan D, Müller E, Stangl V, Baumann G, Stangl K, Laule M, Knebel F. Recovery of left ventricular and left atrial mechanics in various entities of aortic stenosis 12 months after TAVI. *Eur Heart J Cardiovasc Imaging*. 2014;15:389-98.
13. Kamperidis V, Joyce E, Debonnaire P, Katsanos S, van Rosendaal PJ, van der Kley F, Sianos G, Bax JJ, Ajmone Marsan N, Delgado V. Left ventricular functional recovery and remodeling in low-flow low-gradient severe aortic stenosis after transcatheter aortic valve implantation. *J Am Soc Echocardiogr*. 2014;27:817-25.
14. Carter-Storch R, Möller JE, Christensen NL, Irmukhadenov A, Rasmussen LM, Pecini R, Øvrehus KA, Søndergård EV, Marcussen N, Dahl JS. Postoperative Reverse Remodeling and Symptomatic Improvement in Normal-Flow Low-Gradient Aortic Stenosis After Aortic Valve Replacement. *Circ Cardiovasc Imaging*. 2017;10:e006580.
15. Dahou A, Clavel MA, Dumesnil JG, Capoulade R, Ribeiro HB, O'Connor K, Mathieu P, Beaudoin J, Larose É, Rodés-Cabau J, Pibarot P. Impact of AVR on LV Remodeling and Function in Paradoxical Low-Flow, Low-Gradient Aortic Stenosis With Preserved LVEF. *JACC Cardiovasc Imaging*. 2017;10:88-9.
16. Schewel J, Schewel D, Frerker C, Wohlmuth P, Kuck KH, Schäfer U. Invasive hemodynamic assessments during transcatheter aortic valve implantation: comparison of patient outcomes in higher vs. lower transvalvular gradients with respect to left ventricular ejection fraction. *Clin Res Cardiol*. 2016;105:59-71.
17. Mohty D, Magne J, Deltreuil M, Aboyans V, Echahidi N, Cassat C, Pibarot P, Laskar M, Viot P. Outcome and impact of surgery in paradoxical low-flow, low-gradient severe aortic stenosis and preserved left ventricular ejection fraction: a cardiac catheterization study. *Circulation*. 2013;128:S235-42.
18. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Eur Heart J*. 2012;33:2403-18.
19. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. *Circulation*. 2007;115:2856-64.
20. Minners J, Allgeier M, Gohlke-Baerwolf C, Kienzle RP, Neumann FJ, Jander N. Inconsistent grading of aortic valve stenosis by current guidelines: haemodynamic studies in patients with apparently normal left ventricular function. *Heart*. 2010;96:1463-8.
21. Généreux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson LG, Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto WY, Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, Kodali SK, Smith CR, Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the extent of cardiac damage. *Eur Heart J*. 2017;38:3351-8.
22. Zusman O, Pressman GS, Banai S, Finkelstein A, Topilsky Y. Intervention Versus Observation in Symptomatic Patients With Normal Flow Low Gradient Severe Aortic Stenosis. *JACC Cardiovasc Imaging*. 2018;11:1225-32.
23. Dumesnil JG, Pibarot P, Carabello B. Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment. *Eur Heart J*. 2010;31:281-9.
24. Herrmann S, Störk S, Niemann M, Lange V, Strotmann JM, Frantz S, Beer M, Gattenlöhner S, Voelker W, Ertl G, Weidemann F. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. *J Am Coll Cardiol*. 2011;58:402-12.
25. Gertz ZM, Pibarot P, Douglas PS, Elmariha S, Alu MC, McAndrew T, Zhang Y, Hodson RW, Hahn RT, Weissman NJ, Lindman BR, Clavel MA, Lerakis S, Abbas AE, Thourani VH, Kodali S, Kapadia S, Suri RM, Makkar R, Mack MJ, Leon MB, Herrmann HC. Implications of Left Ventricular Geometry in Low-Flow Aortic Stenosis: A PARTNER 2 Trial Subanalysis. *JACC Cardiovasc Imaging*. 2019;12:367-8.
26. Mangner N, Stachel G, Woitek F, Haussig S, Schlotter F, Höllriegel R, Adam J, Lindner A, Mohr FW, Schuler G, Kiefer P, Leontyev S, Borger MA, Thiele H, Holzhey D, Linke A. Predictors of Mortality and Symptomatic Outcome of Patients With Low-Flow Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. *J Am Heart Assoc*. 2018 Apr 13;7(8).
27. Gertz ZM, Raina A, O'Donnell W, McCauley BD, Shellenberger C, Kolansky DM, Wilensky RL, Forfia PR, Herrmann HC. Comparison of invasive and noninvasive assessment of aortic stenosis severity in the elderly. *Circ Cardiovasc Interv*. 2012;5:406-14.

## Supplementary data

### Supplementary Appendix 1. Methods.

**Supplementary Figure 1.** Echocardiographic assessment of the different subgroups of LG-AS.

**Supplementary Figure 2.** Schematic of haemodynamic parameters in the different subgroups of LG-AS.

**Supplementary Figure 3.** Schematic of cardiopulmonary circulation and changes in haemodynamic parameters according to LG-AS subgroup.

**Supplementary Table 1.** Invasive haemodynamic data.

**Supplementary Table 2.** Procedural and post-procedural complications according to VARC-2 criteria.

**Supplementary Table 3.** Predictors of one-year mortality.

**Moving image 1A.** Apical four-chamber view of a patient with NFLG-AS.

**Moving image 1B.** Parasternal long-axis view of a patient with NFLG-AS.

**Moving image 2A.** Apical four-chamber view of a patient with PLFLG-AS.

**Moving image 2B.** Parasternal long-axis view of a patient with PLFLG-AS.

**Moving image 3A.** Apical four-chamber view of a patient with CLFLG-AS.

**Moving image 3B.** Parasternal long-axis view of a patient with CLFLG-AS.

The supplementary data are published online at:  
<https://eurointervention.pconline.com/doi/10.4244/EIJ-D-19-00399>



## **Supplementary data**

### **Supplementary Appendix 1. Methods**

#### **Echocardiography**

All patients underwent an extended echocardiographic examination including assessment of the aortic valve by measuring MG (MG [echo]), aortic peak velocity, AVA via the continuity equation, evaluation of aortic regurgitation (AR), mitral regurgitation (MR) and tricuspid regurgitation (TR) and left ventricular ejection fraction (LVEF) by the Simpson method. Furthermore, left atrial (LA), LV end-systolic diameter (LVESD) and end-diastolic diameter (LVEDD), thickness of interventricular septum (IVS) and posterior wall (PW), as well as the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity ( $E/E'$ ), and tricuspid annular plane systolic excursion (TAPSE) were documented.

#### **Cardiac catheterisation**

All patients underwent cardiac left and right heart catheterisation directly before and after the TAVR procedure. A 7 Fr Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA, USA) was routinely used for haemodynamic measurements.

#### **Invasive assessment of left and right heart haemodynamics**

Left ventricular end-systolic (LVESP) and end-diastolic (LVEDP), systolic (SAP) and diastolic arterial (DAP) as well as pulmonary capillary wedge (PCWP), right atrial (RAP), systolic (sPAP) and diastolic (dPAP) pulmonary artery pressures (PAP) were recorded. Cardiac output (CO) was determined using the thermodilution method. Left (LVSWI) and right ventricular stroke work index (RVSWI) were calculated as  $LVSWI = SVI * (MAP - PCWP) * 0.0136$  and  $RVSWI = SVI * (mPAP - RAP) * 0.0136$ , further left (LCWI) and right cardiac work index (RCWI) were calculated as  $LCWI = CI * MAP * 0.0136$  and  $RCWI = CI * mPAP * 0.0136$ .


#### **Valvular resistance and afterload assessment**

AVA was calculated using the Gorlin formula as  $AVA = (CO / \text{systolic ejection period [SEP]} * HR) / 44.3 \sqrt{MG \text{ [invasive]}}$ . Aortic valve gradients were assessed by simultaneous measurement of left ventricular and aortic pressures. MG [invasive] was calculated via the area under the pressure curve. Valvular resistance (VR) was calculated as  $VR = (MG \text{ [invasive]} * HR * SEP / CO) * 1.33$ . Systemic

vascular resistance index (SVRI) was calculated as  $SVRI = (MAP - RAP) * 80 / CI$ . The valvuloarterial impedance/LV global afterload ( $Z_{va}$ ) was calculated as  $Z_{va} = LVESP / SVI$ .

### **Transcatheter aortic valve implantation procedure**

According to the device availability at different time points, commercially available valves (Medtronic CoreValve, Edwards SAPIEN and Centra, Direct Flow Medical, JenaValve, Boston Scientific Lotus Edge Valve System, St. Jude Portico and New Valve Technology Allegra) were **implanted**.



**Supplementary Figure 1.** Echocardiographic assessment of the different subgroups of LG-AS.


1A, 2A, 3A. Apical four-chamber view (Moving image 1A-Moving image 3A).

1B, 2B, 3B. Parasternal long-axis view (Moving image 1B-Moving image 3B).

1C, 2C, 3C. Continuous-wave Doppler through the aortic valve.


1D, 2D, 3D. Pulsed-wave Doppler through the aortic valve.

AS: aortic stenosis; AVA: aortic valve area; AVAi: indexed aortic valve area; CLFLG: classic low-flow low-gradient; LVEF: left ventricular ejection fraction; MG [echo]: echocardiographically measured mean transvalvular gradient; NFLG: normal-flow low-gradient; PLFLG: paradoxical low-flow low-gradient; SVI: stroke volume index



**Supplementary Figure 2.** Schematic of haemodynamic parameters in the different subgroups of LG-AS.

Schematic of the haemodynamic parameters split into the followed aspects: global afterload, systemic resistance, valvular resistance and LV function. Global afterload consisting of systemic and valvular resistance increases from NFLG-AS to PLFLG-AS and CLFLG-AS (shown by increasing circles), while the level of parameters between PLFLG-AS and CLFLG-AS is similar (same size circle). LV function decreases from NFLG-AS over PLFLG-AS to CLFLG-AS (shown by decreasing circles).



**Supplementary Figure 3.** Schematic of cardiopulmonary circulation and changes in haemodynamic parameters according to LG-AS subgroup.

Symbols describing the changes in haemodynamic variables after TAVR compared to baseline: ↑ mild increase; ↑↑ moderate increase; ↑↑↑ severe increase; ↓ mild decrease; ↓↓ moderate decrease; ↓↓↓ severe decrease.

CI: cardiac index; CO: cardiac output; LG-AS: low-gradient aortic stenosis; LV: left ventricular; LVSWI: left ventricular stroke work index; PAP: pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; PVRI: pulmonary vascular resistance index; RAP: right atrial pressure; SAP: systemic arterial pressure; SVI: stroke volume index; SVRI: systemic vascular resistance index; Zva: valvuloarterial impedance

**Supplementary Table 1. Invasive haemodynamic data.**

|                                                          |                 | <b>ALL</b><br><b>n=600</b> | <b>NFLG-AS</b><br><b>n=296</b> | <b>PLFLG-AS</b><br><b>n=153</b> | <b>CLFLG-AS</b><br><b>n=151</b> | <b><i>p</i>-value</b> |
|----------------------------------------------------------|-----------------|----------------------------|--------------------------------|---------------------------------|---------------------------------|-----------------------|
| <b>Aortic stenosis severity</b>                          |                 |                            |                                |                                 |                                 |                       |
| Aortic valve area, cm <sup>2</sup>                       | pre TAVR        | 0.83±0.20                  | 0.91±0.18*†                    | 0.74±0.20*                      | 0.77±0.19†                      | <b>&lt;0.001</b>      |
|                                                          | post TAVR       | 2.65±0.71                  | 2.68±0.70                      | 2.61±0.73                       | 2.63±0.72                       | 0.661                 |
|                                                          | <i>p</i> -value | <b>&lt;0.001</b>           | <b>&lt;0.001</b>               | <b>&lt;0.001</b>                | <b>&lt;0.001</b>                |                       |
| Aortic valve area index, cm <sup>2</sup> /m <sup>2</sup> | pre TAVR        | 0.46±0.11                  | 0.50±0.09*†                    | 0.41±0.11*                      | 0.42±0.11†                      | <b>&lt;0.001</b>      |
|                                                          | post TAVR       | 1.46±0.42                  | 1.49±0.43                      | 1.44±0.40                       | 1.44±0.41                       | 0.357                 |
|                                                          | <i>p</i> -value | <b>&lt;0.001</b>           | <b>&lt;0.001</b>               | <b>&lt;0.001</b>                | <b>&lt;0.001</b>                |                       |
| Mean transvalvular gradient, MG [invasive], mmHg         | pre TAVR        | 29.4±7.1                   | 31.2±6.3*†                     | 28.8±6.8*‡                      | 26.5±7.9†‡                      | <b>&lt;0.001</b>      |
|                                                          | post TAVR       | 6.4±4.5                    | 6.5±4.7                        | 6.6±4.7                         | 6.0±3.6                         | 0.401                 |
|                                                          | <i>p</i> -value | <b>&lt;0.001</b>           | <b>&lt;0.001</b>               | <b>&lt;0.001</b>                | <b>&lt;0.001</b>                |                       |
| Peak-to-peak pressure, mmHg                              | pre TAVR        | 28.4±12.4                  | 29.7±11.7†                     | 29.1±13.9                       | 25.2±11.7†                      | <b>0.001</b>          |
|                                                          | post TAVR       | 2.2±3.1                    | 2.1±2.7                        | 2.7±4.0                         | 1.9±2.6                         | 0.087                 |

|                                                                           |                 |                  |                  |                  |                  |                  |
|---------------------------------------------------------------------------|-----------------|------------------|------------------|------------------|------------------|------------------|
|                                                                           | <i>p</i> -value | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Valvular resistance, dynes/cm <sup>5</sup>                                | pre TAVR        | 209.4±71.5       | 193.1±52.7*†     | 235.2±81.5*      | 215.4±83.6†      | <b>&lt;0.001</b> |
|                                                                           | post TAVR       | 30.0±17.3        | 29.6±17.9        | 30.5±16.6        | 30.2±16.9        | 0.873            |
|                                                                           | <i>p</i> -value | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| <b>Systemic vascular load</b>                                             |                 |                  |                  |                  |                  |                  |
| Systolic AP, mmHg                                                         | pre TAVR        | 108.7±23.1       | 114.3±23.0*†     | 107.9±23.3*‡     | 98.6±19.3†‡      | <b>&lt;0.001</b> |
|                                                                           | post TAVR       | 127.6±23.4       | 132.5±23.0*†     | 124.8±24.1*      | 120.8±21.3†      | <b>&lt;0.001</b> |
|                                                                           | <i>p</i> -value | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Diastolic AP, mmHg                                                        | pre TAVR        | 50.9±9.5         | 50.4±10.7        | 52.6±14.6        | 50.3±9.5         | 0.121            |
|                                                                           | post TAVR       | 53.1±10.3        | 52.5±10.7        | 53.1±9.7         | 54.4±9.9         | 0.186            |
|                                                                           | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.002</b>     | 0.629            | <b>&lt;0.001</b> |                  |
| Mean AP, mmHg                                                             | pre TAVR        | 70.4±13.5        | 71.9±13.3†       | 71.3±15.6‡       | 66.6±11.0†‡      | <b>&lt;0.001</b> |
|                                                                           | post TAVR       | 77.8±13.0        | 79.0±13.5        | 76.9±12.9        | 76.3±11.9        | 0.087            |
|                                                                           | <i>p</i> -value | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Systemic vascular resistance index, dynes/cm <sup>5</sup> /m <sup>2</sup> | pre TAVR        | 2,235±756        | 1,948±532*†      | 2,703±924*‡      | 2,315±684†‡      | <b>&lt;0.001</b> |

|                                                   |                 |                  |                  |                  |                  |                  |
|---------------------------------------------------|-----------------|------------------|------------------|------------------|------------------|------------------|
|                                                   | post TAVR       | 2,313±820        | 2,116±734*†      | 2,574±913*       | 2,447±790†       | <b>&lt;0.001</b> |
|                                                   | <i>p</i> -value | <b>0.011</b>     | <b>&lt;0.001</b> | <b>0.043</b>     | 0.051            |                  |
| <b>LV global afterload</b>                        |                 |                  |                  |                  |                  |                  |
| Valvuloarterial impedance, mmHg/ml/m <sup>2</sup> | pre TAVR        | 4.2±1.4          | 3.3±0.7*†        | 5.2±1.5*         | 4.9±1.4†         | <b>&lt;0.001</b> |
|                                                   | post TAVR       | 4.0±1.4          | 3.4±1.1*†        | 4.4±1.4*         | 4.6±1.6†         | <b>&lt;0.001</b> |
|                                                   | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.013</b>     | <b>&lt;0.001</b> | <b>0.004</b>     |                  |
| <b>LV systolic function</b>                       |                 |                  |                  |                  |                  |                  |
| Left ventricular end-systolic pressure, mmHg      | pre TAVR        | 137.0±23.9       | 144.0±22.8*†     | 136.6±24.3*‡     | 123.9±20.0†‡     | <b>&lt;0.001</b> |
|                                                   | post TAVR       | 129.8±23.4       | 134.6±23.1*†     | 127.6±23.8*      | 122.6±21.4†      | <b>&lt;0.001</b> |
|                                                   | <i>p</i> -value | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> | 0.426            |                  |
| Left ventricular end-diastolic pressure, mmHg     | pre TAVR        | 14.5±6.2         | 14.4±6.4         | 13.2±5.4‡        | 16.0±6.1‡        | <b>0.001</b>     |
|                                                   | post TAVR       | 17.8±7.2         | 17.9±7.2         | 16.8±6.6         | 18.4±7.8         | 0.157            |
|                                                   | <i>p</i> -value | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Stroke volume index, ml/m <sup>2</sup>            | pre TAVR        | 36.0±11.8        | 45.4±8.6*†       | 27.4±5.7*        | 26.5±5.9†        | <b>&lt;0.001</b> |
|                                                   | post TAVR       | 37.0±1.9         | 43.0±11.6 *†     | 31.7±9.2*        | 29.9±7.9†        | <b>&lt;0.001</b> |

|                                                                       |                 |                  |                  |                  |                  |                  |
|-----------------------------------------------------------------------|-----------------|------------------|------------------|------------------|------------------|------------------|
|                                                                       | <i>p</i> -value | 0.110            | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Cardiac output, l/min                                                 | pre TAVR        | 4.1±1.2          | 4.8±1.1*†        | 3.4±0.8*         | 3.5±0.8†         | <b>&lt;0.001</b> |
|                                                                       | post TAVR       | 4.4±1.4          | 5.0±1.4*†        | 3.9±1.2*         | 3.9±1.0†         | <b>&lt;0.001</b> |
|                                                                       | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.054</b>     | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Cardiac index, l/min/m <sup>2</sup>                                   | pre TAVR        | 2.3±0.6          | 2.6±0.6*†        | 1.9±0.4*         | 1.9±0.4†         | <b>&lt;0.001</b> |
|                                                                       | post TAVR       | 2.4±0.7          | 2.7±0.7*†        | 2.1±0.6*         | 2.1±0.5†         | <b>&lt;0.001</b> |
|                                                                       | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.058</b>     | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Pulmonary capillary wedge pressure, mmHg                              | pre TAVR        | 18.6±8.7         | 17.2±8.1†        | 17.9±7.2‡        | 22.2±10.0†‡      | <b>&lt;0.001</b> |
|                                                                       | post TAVR       | 20.8±9.0         | 19.4±8.4†        | 20.5±8.3‡        | 23.9±10.0†‡      | <b>&lt;0.001</b> |
|                                                                       | <i>p</i> -value | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> | <b>0.003</b>     |                  |
| Left ventricular stroke work index, g/m <sup>-1</sup> /m <sup>2</sup> | pre TAVR        | 26.1±12.3        | 34.0±11.1*†      | 20.1±7.7*‡       | 16.3±6.8†‡       | <b>&lt;0.001</b> |
|                                                                       | post TAVR       | 29.2±13.3        | 35.2±13.8*†      | 25.1±10.5*       | 21.2±7.9†        | <b>&lt;0.001</b> |
|                                                                       | <i>p</i> -value | <b>&lt;0.001</b> | 0.116            | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Left cardiac work index, kg/m <sup>-1</sup> /m <sup>2</sup>           | pre TAVR        | 2.20±0.82        | 2.61±0.84*†      | 1.85±0.61*       | 1.73±0.51†       | <b>&lt;0.001</b> |
|                                                                       | post TAVR       | 2.60±0.94        | 2.95±1.01*†      | 2.26±0.77*‡      | 2.21±0.61†‡      | <b>&lt;0.001</b> |

|                                                                             |                 |                  |              |                  |                  |                  |
|-----------------------------------------------------------------------------|-----------------|------------------|--------------|------------------|------------------|------------------|
|                                                                             | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.051</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| <b>Right-sided haemodynamic data</b>                                        |                 |                  |              |                  |                  |                  |
| Systolic PAP, mmHg                                                          | pre TAVR        | 45.7±15.2        | 43.7±15.0†   | 44.1±15.5‡       | 51.3±14.1†‡      | <b>&lt;0.001</b> |
|                                                                             | post TAVR       | 47.9±15.5        | 46.0±15.6†   | 46.9±14.9‡       | 53.0±14.8†‡      | <b>&lt;0.001</b> |
|                                                                             | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.002</b> | <b>0.001</b>     | <b>0.022</b>     |                  |
| Diastolic PAP, mmHg                                                         | pre TAVR        | 18.3±7.8         | 16.5±7.4†    | 17.7±7.2‡        | 22.3±7.8†‡       | <b>&lt;0.001</b> |
|                                                                             | post TAVR       | 19.4±8.3         | 17.9±7.7†    | 19.2±8.4‡        | 22.7±8.4†‡       | <b>&lt;0.001</b> |
|                                                                             | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.004</b> | <b>0.008</b>     | 0.251            |                  |
| Mean PAP, mmHg                                                              | pre TAVR        | 27.6±9.8         | 25.7±9.6†    | 26.6±9.2‡        | 32.3±9.4†‡       | <b>&lt;0.001</b> |
|                                                                             | post TAVR       | 29.3±10.3        | 27.8±10.3†   | 28.6±9.7‡        | 32.9±9.8†‡       | <b>&lt;0.001</b> |
|                                                                             | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.001</b> | <b>&lt;0.001</b> | 0.177            |                  |
| Right atrial pressure, mmHg                                                 | pre TAVR        | 10.0±5.6         | 8.8±5.3†     | 9.8±5.1‡         | 12.5±7.2†‡       | <b>&lt;0.001</b> |
|                                                                             | post TAVR       | 10.9±5.7         | 9.8±5.2†     | 11.0±5.3‡        | 13.1±6.6†‡       | <b>&lt;0.001</b> |
|                                                                             | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.001</b> | <b>&lt;0.001</b> | 0.115            |                  |
| Pulmonary vascular resistance index, dynes/cm <sup>-5</sup> /m <sup>2</sup> | pre TAVR        | 339±318          | 267±252*†    | 383±350*         | 439±367†         | <b>&lt;0.001</b> |

|                                                                        |                 |                  |              |                  |                  |                  |
|------------------------------------------------------------------------|-----------------|------------------|--------------|------------------|------------------|------------------|
|                                                                        | post TAVR       | 298±334          | 254±292†     | 330±367          | 351±368†         | <b>0.008</b>     |
|                                                                        | <i>p</i> -value | <b>0.003</b>     | 0.373        | 0.128            | <b>0.007</b>     |                  |
| Right ventricular stroke work index, g/m <sup>-1</sup> /m <sup>2</sup> | pre TAVR        | 8.6±4.7          | 10.4±5.4*†   | 6.3±2.6*         | 7.4±3.4†         | <b>&lt;0.001</b> |
|                                                                        | post TAVR       | 9.1±4.8          | 10.3±5.3*†   | 7.7±3.7*         | 8.1±4.0†         | <b>&lt;0.001</b> |
|                                                                        | <i>p</i> -value | <b>0.004</b>     | 0.877        | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |
| Right cardiac work index, kg/m <sup>-1</sup> /m <sup>2</sup>           | pre TAVR        | 0.85±0.38        | 0.93±0.43*†  | 0.68±0.27*‡      | 0.84±0.30†‡      | <b>&lt;0.001</b> |
|                                                                        | post TAVR       | 0.96±0.44        | 1.04±0.50*   | 0.82±0.32*       | 0.96±0.37†       | <b>&lt;0.001</b> |
|                                                                        | <i>p</i> -value | <b>&lt;0.001</b> | <b>0.052</b> | <b>&lt;0.001</b> | <b>&lt;0.001</b> |                  |

All values are mean±SD.

\*p<0.0167 NFLG-AS vs PLFLG-AS. †p<0.0167 NFLG-AS vs CLFLG-AS. ‡p<0.0167 CLFLG-AS vs PLFLG-AS.

AP: arterial pressure; LG-AS: low-gradient aortic stenosis; PAP: pulmonary artery pressure

**Supplementary Table 2. Procedural and post-procedural complications according to VARC-2 criteria.**

|                                             | <b>ALL<br/>n=600</b> | <b>NFLG-AS<br/>n=296</b> | <b>PLFLG-<br/>AS<br/>n=153</b> | <b>CLFLG-<br/>AS<br/>n=151</b> | <b>p-<br/>value</b> |
|---------------------------------------------|----------------------|--------------------------|--------------------------------|--------------------------------|---------------------|
| <b>Device success</b>                       |                      |                          |                                |                                |                     |
| Acute device success                        | 575 (95.8)           | 285 (96.3)               | 147 (96.1)                     | 143 (94.7)                     | 0.719               |
| Intraprocedural mortality                   | 2 (0.3)              | 0 (0)                    | 1 (0.7)                        | 1 (0.7)                        | 0.499               |
| Correct positioning of one prosthetic valve | 583 (97.2)           | 288 (97.3)               | 148 (96.7)                     | 147 (97.4)                     | 0.949               |
| Mean aortic valve gradient $\geq 20$ mmHg   | 4 (0.7)              | 2 (0.7)                  | 1 (0.7)                        | 1 (0.7)                        | 1.000               |
| Implantation of a second prosthetic valve   | 9 (1.5)              | 5 (1.7)                  | 2 (1.3)                        | 2 (1.3)                        | 1.000               |
| Moderate to severe prosthetic regurgitation | 8 (1.3)              | 4 (1.4)                  | 2 (1.3)                        | 2 (1.3)                        | 1.000               |
| Conversion to open surgery                  | 4 (0.7)              | 2 (0.7)                  | 1 (0.7)                        | 1 (0.7)                        | 1.000               |
| <b>Clinical efficacy at discharge</b>       |                      |                          |                                |                                |                     |
| All-cause mortality at discharge            | 38 (6.3)             | 13 (4.4)                 | 10 (6.5)                       | 15 (9.9)                       | <b>0.049</b>        |
| Major stroke at discharge                   | 30 (5.0)             | 19 (6.4)                 | 7 (4.6)                        | 4 (2.6)                        | 0.221               |
| Acute kidney injury (stage 2/3)             | 47 (7.8)             | 22 (7.4)                 | 11 (7.2)                       | 14 (9.3)                       | 0.752               |
| Major vascular complication                 | 16 (2.7)             | 6 (2)                    | 9 (5.9)                        | 1 (0.7)                        | 0.052               |
| Minor vascular complication                 | 65 (10.8)            | 33 (11.1)                | 17 (11.1)                      | 15 (9.9)                       | 0.941               |
| Life-threatening or disabling bleeding      | 38 (6.3)             | 17 (5.7)                 | 13 (8.5)                       | 8 (5.3)                        | 0.452               |
| Major bleeding                              | 87 (14.5)            | 46 (15.5)                | 18 (11.8)                      | 23 (15.2)                      | 0.551               |
| New permanent pacemaker implantation        | 98 (16.3)            | 48 (16.2)                | 27 (17.6)                      | 23 (15.2)                      | 0.859               |
| <b>Clinical efficacy at 1 year</b>          |                      |                          |                                |                                |                     |
| All-cause mortality at 1 year               | 146 (24.3)           | 59 (19.9)†               | 36 (23.5)                      | 51 (33.8)†                     | <b>0.006</b>        |
| Major stroke at 1 year                      | 17 (4.0)             | 10 (4.4)                 | 4 (3.7)                        | 3 (3.1)                        | 0.853               |

All values are n (%).

\*p<0.0167 NFLG-AS vs PLFLG-AS. †p<0.0167 NFLG-AS vs CLFLG-AS. ‡p<0.0167 CLFLG-AS vs PLFLG-AS.

LG-AS: low-gradient aortic stenosis

**Supplementary Table 3. Predictors of one-year mortality.**

|                          | NFLG-AS             |           |              |                        |           |              | PLFLG-AS            |           |              | CLFLG-AS            |           |              |                        |           |         |
|--------------------------|---------------------|-----------|--------------|------------------------|-----------|--------------|---------------------|-----------|--------------|---------------------|-----------|--------------|------------------------|-----------|---------|
|                          | Univariate analysis |           |              | Multivariable analysis |           |              | Univariate analysis |           |              | Univariate analysis |           |              | Multivariable analysis |           |         |
|                          | HR                  | 95% CI    | p-value      | HR                     | 95% CI    | p-value      | HR                  | 95% CI    | p-value      | HR                  | 95% CI    | p-value      | HR                     | 95% CI    | p-value |
| Male gender              | 1.38                | 0.82-2.32 | 0.226        |                        |           |              | 1.06                | 0.53-2.08 | 0.878        | 1.36                | 0.75-2.49 | 0.315        |                        |           |         |
| Age, per year            | 1.08                | 1.04-1.13 | <b>0.001</b> | 1.09                   | 1.05-1.14 | <b>0.001</b> | 1.06                | 1.00-1.12 | <b>0.046</b> | 1.04                | 1.00-1.08 | <b>0.036</b> | 1.03                   | 0.99-1.08 | 0.108   |
| Impaired renal function* | 1.93                | 1.06-3.51 | <b>0.032</b> | 1.58                   | 0.86-2.91 | 0.141        | 1.25                | 0.62-2.55 | 0.534        | 1.56                | 0.84-2.89 | 0.155        |                        |           |         |
| Atrial fibrillation      | 1.36                | 0.82-2.28 | 0.238        |                        |           |              | 0.79                | 0.41-1.53 | 0.478        | 2.01                | 1.10-3.67 | <b>0.024</b> | 1.78                   | 0.96-3.34 | 0.068   |
| Pulmonary hypertension†  | 2.65                | 1.53-4.59 | <b>0.001</b> | 2.92                   | 1.65-5.14 | <b>0.001</b> | 0.83                | 0.43-1.62 | 0.585        | 2.05                | 0.92-4.56 | 0.078        |                        |           |         |
| History of stroke        | 0.81                | 0.40-1.64 | 0.555        |                        |           |              | 1.05                | 0.44-2.53 | 0.909        | 0.93                | 0.42-2.07 | 0.863        |                        |           |         |
| LVEF, per %              | 0.14                | 0.02-1.00 | <b>0.050</b> | 0.42                   | 0.06-3.15 | 0.393        | 9.79                | 0.00-3290 | 0.582        | 0.51                | 0.02-1.27 | 0.070        |                        |           |         |

\* Glomerular filtration rate <60 mL/min/1.73m<sup>2</sup>. † Mean pulmonary artery pressure ≥25 mmHg.

CI: confidence interval; HR: hazard ratio; LG-AS: low-gradient aortic stenosis; LVEF: left ventricular ejection fraction